Pharmacological profile of a 17β-heteroaryl-substituted neuroactive steroid

@article{Hogenkamp2014PharmacologicalPO,
  title={Pharmacological profile of a 17$\beta$-heteroaryl-substituted neuroactive steroid},
  author={Derk J. Hogenkamp and Minhtam B. Tran and Ryan F. Yoshimura and Timothy B C Johnstone and Richard C. Kanner and Kelvin W. Gee},
  journal={Psychopharmacology},
  year={2014},
  volume={231},
  pages={3517-3524}
}
RationaleIn order to improve upon the pharmacological properties of the neuroactive steroid ganaxolone, it was used as the starting point in the design of novel neurosteroids that replace the 17β-acetyl side chain with an isoxazole bioisostere.ObjectivesUCI-50027 (3-[3α-hydroxy-3β-methyl-5α-androstan-17β-yl]-5-(hydroxymethyl)isoxazole) was designed as an orally active neuroactive steroid specifically targeted at the gamma-aminobutyric acid(A) receptor (GABAAR).MethodsUCI-50027 was tested in… 
Photoaffinity labeling identifies an intersubunit steroid-binding site in heteromeric GABA type A (GABAA) receptors
TLDR
Results provide a first insight into the structure-activity relationship at the GABAAR β+–α− subunit interface steroid-binding site and identify several steroid PAMs that act via other sites.
Benzodiazepine and neuroactive steroid combinations in rats: anxiolytic-like and discriminative stimulus effects
TLDR
Although drug interactions depended on the constituent drugs, the combination tested, and the behavioral endpoint; a combination was identified that would be predicted to result in supra-additive anxiolytic-like effects with predominantly additive discriminative stimulus effects.
Breakthroughs in neuroactive steroid drug discovery.
Clinical Potential of Neurosteroids for CNS
TLDR
Recent advances in US National Institutes of Health-sponsored and other clinical studies of neurosteroids for CNS disorders are described and synthetic analogs have several advantages over natural neurosteroid for clinical use because of their superior bioavailability and safety trends.
Clinical Potential of Neurosteroids for CNS Disorders.
GABA Receptors and the Pharmacology of Sleep.
Current GABAergic sleep-promoting medications were developed pragmatically, without making use of the immense diversity of GABAA receptors. Pharmacogenetic experiments are leading to an understanding
...
1
2
...

References

SHOWING 1-10 OF 25 REFERENCES
Characterization of the anticonvulsant properties of Ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acid(A) receptor
TLDR
Data indicate that ganaxolone is a high-affinity, stereoselective, positive allosteric modulator of the GABAA receptor complex that exhibits potent anticonvulsant activity across a range of animal procedures.
Synthesis and in Vitro Activity of 3β-Substituted-3α-hydroxypregnan-20-ones: Allosteric Modulators of the GABAA Receptor†
Two naturally occurring metabolites of progesterone, 3α-hydroxy-5α- and 5β-pregnan-20-one (1 and 2), are potent allosteric modulators of the GABAA receptor. Their therapeutic potential as
Enaminone amides as novel orally active GABAA receptor modulators.
TLDR
Structural-activity relationship (SAR) studies resulted in the synthesis of the c-Bu amide 16h with an in vitro potency of 7 nM based on inhibition of [35S]TBPS binding, which was an orally active anxiolytic in the mouse light-dark paradigm.
Substituted 3beta-phenylethynyl derivatives of 3alpha-hydroxy-5alpha-pregnan-20-one: remarkably potent neuroactive steroid modulators of gamma-aminobutyric acidA receptors.
TLDR
The remarkable potency of Co 152791 as a positive allosteric modulator of GABAA receptors may be explained by its interaction with an auxiliary binding pocket in the neuroactive steroid binding site and hinders metabolism of the 3alpha-hydroxy group contributing to the exceptional anticonvulsant potency of this compound relative to other neuroactive steroids.
Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy.
TLDR
Clinical data to date support a favourable safety profile with somnolence, an extension of GABAergic activity, being the most frequently reported adverse event at higher doses, and open-label data in paediatric patients with intractable epilepsy suggest that ganaxolone may be effective in treating infantile spasms.
Limiting Activity at β1-Subunit-Containing GABAA Receptor Subtypes Reduces Ataxia
TLDR
These findings provide an alternative strategy for designing anxioselective allosteric modulators of the GABAAR with BZ-like anxiolytic efficacy by reducing or eliminating activity at β1-subunit-containing GABAARs.
Neurosteroids as endogenous regulators of seizure susceptibility and use in the treatment of epilepsy
TLDR
Neurosteroids such as allopregnanolone are positive allosteric modulators of γ‐aminobutyric acid (GABA)A receptors with powerful antiseizure activity in diverse animal models with promise in the treatment of diverse forms of epilepsy.
Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators
TLDR
A selective α7 nAChR-positive allosteric modulator (PAM) from a library of GABAA receptor PAMs is generated, which corrects sensory-gating deficits and improves working memory, effects consistent with cognitive enhancement in rodent models.
Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator
TLDR
Results suggest that β2/3-subunit subtype-selective GABAA receptor-positive allosteric modulators not only have reduced sedative liability, but also a reduction in other central side effects commonly associated with broader GabAA receptor activation.
...
1
2
3
...